


TCF1 Blocking Peptide

✓ 100 µg (100 sections)

Orders ■ 877-616-CELL (2355) orders@cellsignal.com
Support ■ 877-678-TECH (8324) info@cellsignal.com
Web ■ www.cellsignal.com

New 08/07

This product is for *in vitro* research use only and is not intended for use in humans or animals.



Immunohistochemical analysis of paraffin-embedded human lung carcinoma using TCF1 (C63D9) Rabbit mAb #2203 in the presence of control peptide (left) or TCF1 Blocking Peptide (right).

Description: This peptide is used to block TCF1 (C63D9) Rabbit mAb #2203 reactivity in immunohistochemistry protocols.

Background: LEF1 and TCF are members of the high mobility group (HMG) DNA binding protein family of transcription factors which consists of the following: Lymphoid enhancer factor 1 (LEF1), T Cell Factor 1 (TCF1), TCF3 and TCF4 (1). LEF1 and TCF1 were originally identified as important factors regulating early lymphoid development (2) and act downstream in Wnt signaling. LEF1/TCF bind to Wnt response elements to provide a docking site for β-catenin, which translocates to the nucleus to promote the transcription of target genes upon activation of Wnt signaling (3). LEF1/TCF proteins are dynamically expressed during development and aberrant activation of the Wnt signaling pathway is involved in many types of cancers including colon cancer (4,5).

Quality Control: The quality of the peptide was evaluated by reversed-phase HPLC and by mass spectrometry. The peptide blocks TCF1 (C63D9) Rabbit mAb #2203 by immunohistochemistry.

Directions for Use: For immunohistochemistry, add twice the volume of peptide as volume of antibody used in 100 µl total volume. Incubate for a minimum of 30 minutes prior to adding the entire volume to the slide. Recommended antibody dilutions can be found on the relevant product data sheet.

Storage: Supplied in 20 mM potassium phosphate (pH 7.0), 50 mM NaCl, 0.1 mM EDTA, 1 mg/ml BSA and 5% glycerol. Store at -20°C.

Companion Products:
TCF1 (C63D9) Rabbit mAb #2203

- Background References:**
- (1) Waterman, M.L. (2004) *Cancer Metastasis Rev.* 23, 41–52.
 - (2) Schilham, M.W. and Clevers, H. (1998) *Semin. Immunol.* 10, 127–132.
 - (3) Brantjes, H. et al. (2002) *Biol. Chem.* 383, 255–261.
 - (4) Reya, T. and Clevers, H. (2005) *Nature* 434, 843–850.
 - (5) Logan, C.Y. and Nusse, R. (2004) *Annu. Rev. Cell Dev. Biol.* 20, 781–810.

